Business Wire

CA-NEXON

12.5.2022 20:49:12 CEST | Business Wire | Press release

Share
Two Worlds Collide When Anime Heroes From DanMachi Meet KonoSuba: Fantastic Days Starting May 26!

Today, leading game publisher Nexon announced free-to-play mobile RPG KonoSuba: Fantastic Days will be teaming up with the popular light novel and manga series, DanMachi , for a limited time crossover event from May 26 to June 9. The anime worlds of KonoSuba: Fantastic Days and DanMachi collide in an all new fantastical encounter!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512006001/en/

In DanMachi , a naive adventurer from the city of Orario named Bell Cranel embarks on a perilous quest in the dungeon-like catacombs underneath the city to fight monsters and a mysterious power. Along the way, Bell meets Hestia, a lonely goddess, and Ais Wallenstein, a powerful swordswoman, plus other new friends who act as his guide through the dangerous Dungeon. The KonoSuba: Fantastic Days X DanMachi collaboration treats Konofans to the unique characters and storylines from the worlds of Axel and Orario.

Konofans can pre-register starting May 12 - 25 here . Once registered, players will be able to earn special rewards through participating in the following events held on the page:

  • Pre-register for Adventure!: The higher the number of cumulative pre-registers, the richer the rewards will be for all players! Players will be eligible to receive these rewards for each milestone achieved in-game from May 12 - 25.
  • Countdown Bonus : Claim additional 300 Quartz daily as a countdown bonus from May 21 - 25.
  • Login Bonuses : From May 26 to June 9, claim special collaboration event login bonuses every day, including two 4★ Guaranteed Recruit Tickets, a free 10x Recruit Ticket, and many other reward items during the two week period!

The KonoSuba: Fantastic Days X DanMachi events include:

  • Goddess Rivalry: DanMachi’s goddess, Hestia, faces off against Konosuba’s Aqua in a new quest and story!
  • Panel Missions : A new feature exclusive to this collaboration event will be introduced that rewards various items and new stones upon clearing missions.
  • New Universal Missions awaits players whose shared goal and progress depend on the number of defeats of new boss, Minotaur.
  • A challenging new Dungeon beckons fearless adventurers!

KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap. ©2019 N・K/K/KMP ©Sumzap, Inc. ©NEXON All Rights Reserved. ©FO-SBCr/D4

To stay up-to-date on KonoSuba: Fantastic Days , visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!

Assets : Press Assets

Social Media: Twitch / Twitter / Instagram / Discord / Facebook

About DanMachi

Is It Wrong to Try to Pick Up Girls in a Dungeon? (also known as DanMachi for short) is based on Fujino Omori’s light novel of the same name which sold more than 12 million copies in total. The story follows the fresh faced Bell Cranel and his growth as he adventures through a giant city called Orario and explores the massive labyrinth “Dungeon” nestled underneath the city.

About KonoSuba: Fantastic Days konosuba.nexon.com

Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World! ”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.

About Nexon America Inc. https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye